Literature DB >> 32589185

Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.

Andrea Hernandez1, Tamar C Brandler1, Fei Chen1, Fang Zhou1, Yuhe Xia2, Judy Zhong2, Andre L Moreira1, Anthony Simms1, Wei Sun1, Xiao Jun Wei1, Aylin Simsir1.   

Abstract

OBJECTIVES: Recent investigations have shown strong correlations between cytology and surgical non-small cell lung carcinoma (NSCLC) specimens in programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) evaluations. Our study aims to evaluate the reproducibility of PD-L1 IHC scoring in NSCLC cytology cell blocks (CBs) and to assess the impact of CB cellularity, method of sample collection, and observer subspecialty on scoring agreement.
METHODS: PD-L1 IHC was performed on 54 NSCLC cytology CBs and was scored independently by seven cytopathologists (three of seven with expertise in pulmonary pathology). Three-tier scoring of negative (<1%), low positive (1%-49%), and high positive (≥50%) and interrater agreement were assessed.
RESULTS: Total and majority agreement among cytopathologists was achieved in 48% and 98% of cases, respectively, with κ = 0.608 (substantial agreement; 95% confidence interval, 0.50-0.72). Cytopathologists with pulmonary pathology expertise agreed in 67% of cases (κ = 0.633, substantial agreement), whereas the remaining cytopathologists agreed in 56% of cases (κ = 0.62, substantial agreement). CB cellularity (P = .36) and sample collection type (P = .59) had no statistically significant difference between raters.
CONCLUSIONS: There is substantial agreement in PD-L1 IHC scoring in cytology CB specimens among cytopathologists. Additional expertise in pulmonary pathology, sample collection type, and CB cellularity have no statistically significant impact on interobserver agreement. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cell block; Cytology; Immunohistochemistry (IHC); Interobserver; Non–small cell lung cancer (NSCLC); Programmed death-ligand 1 (PD-L1); Reproducibility

Year:  2020        PMID: 32589185     DOI: 10.1093/ajcp/aqaa073

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  [Cytopathology and molecular diagnostics of non-small cell lung cancer (NSCLC)].

Authors:  Jana Fassunke; Marianne Engels; Sonja Meemboor; Reinhard Buettner
Journal:  Inn Med (Heidelb)       Date:  2022-06-20

Review 2.  Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.

Authors:  Swati Satturwar; Ilaria Girolami; Enrico Munari; Francesco Ciompi; Albino Eccher; Liron Pantanowitz
Journal:  Diagn Cytopathol       Date:  2022-03-16       Impact factor: 1.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.